In a preclinical BRAFV600E/WT;p53−/− mouse model, treatment with a BRAF inhibitor (PLX4720) and an anti-PD-L1 antibody resulted in a significant tumor regression and strong anti-tumor immune response [89]. Here, BRAF is linked to neoplasm.